Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Triple Negative Breast Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Rectal Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Metastatic Pancreatic Ductal Adenocarcinoma 1Lung Neoplasms 1Intestinal Neoplasms 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Ductal 1Breast Neoplasms 1Adenocarcinoma of Lung 1Adenocarcinoma 1

Interventions

Oxaliplatin 5S 1 (combination) 4Irinotecan 4pembrolizumab 3IFL protocol 3Fluorouracil 3Bevacizumab 3amminedichloro(2-methylpyridine)platinum(II) 2N-(2-fluoro-4-((2-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)carbonylaminopyridin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 2MLN 8237 2Leucovorin 2Gemcitabine 2Folfox protocol 2Fecal Microbiota Transplantation 2Drug Therapy 2Doxorubicin 2Cyclophosphamide 2Cisplatin 2Cetuximab 2Capecitabine 2CGX1321 2ulixertinib 1tivozanib 1titanium silicide 1tislelizumab 1sodium thiosulfate 1sacituzumab govitecan 1remune 1plecanatide 1phosphatidyltransferase, Clostridium butyricum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Gastrointestinal Neoplasms × canakinumab × Clear all
NCT05984602 2026-03-30

A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer

NYU Langone Health

Phase 1 Active not recruiting
9 enrolled
Gastrointestinal

Gastrointestinal Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡